Axsome Therapeutics Inc.

43.44+3.43+8.57%Vol 1.02M1Y Perf -21.02%
Aug 5th, 2022 16:00 DELAYED
BID43.18 ASK44.44
Open39.45 Previous Close40.01
Pre-Market- After-Market43.25
 - -  -0.19 -0.44%
Target Price
89.40 
Analyst Rating
Strong Buy 1.50
Potential %
105.80 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
75.29 
Earnings Rating
Sell
Market Cap1.69B 
Earnings Date
9th Aug 2022
Alpha0.07 Standard Deviation0.41
Beta2.06 

Today's Price Range

38.1244.06

52W Range

19.3851.34

5 Year PE Ratio Range

-17.60-4.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
12.57%
1 Month
1.64%
3 Months
45.67%
6 Months
51.31%
1 Year
-21.02%
3 Years
76.01%
5 Years
636.27%
10 Years
-

TickerPriceChg.Chg.%
AXSM43.443.43008.57
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.02-1.03-0.98
Q04 2021-0.99-0.909.09
Q03 2021-0.94-0.931.06
Q02 2021-0.88-0.862.27
Q01 2021-0.83-0.786.02
Q04 2020-0.73-0.78-6.85
Q03 2020-0.58-0.580.00
Q02 2020-0.54-0.499.26
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.19-12.26Negative
9/2022 QR-1.09-5.83Negative
12/2022 FY-3.99-4.18Negative
12/2023 FY-1.77-98.88Negative
Next Report Date9th Aug 2022
Estimated EPS Next Report-1.19
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1.02M
Shares Outstanding38.91K
Shares Float30.91M
Trades Count13.66K
Dollar Volume42.85M
Avg. Volume959.01K
Avg. Weekly Volume626.16K
Avg. Monthly Volume886.42K
Avg. Quarterly Volume1.36M

Axsome Therapeutics Inc. (NASDAQ: AXSM) stock closed at 43.44 per share at the end of the most recent trading day (a 8.57% change compared to the prior day closing price) with a volume of 1.02M shares and market capitalization of 1.69B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Axsome Therapeutics Inc. CEO is Herriot Tabuteau.

The one-year performance of Axsome Therapeutics Inc. stock is -21.02%, while year-to-date (YTD) performance is 14.98%. AXSM stock has a five-year performance of 636.27%. Its 52-week range is between 19.38 and 51.335, which gives AXSM stock a 52-week price range ratio of 75.29%

Axsome Therapeutics Inc. currently has a PE ratio of -11.70, a price-to-book (PB) ratio of 115.67, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -114.37%, a ROC of -133.19% and a ROE of -266.55%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Axsome Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.19 for the next earnings report. Axsome Therapeutics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Axsome Therapeutics Inc. is Strong Buy (1.5), with a target price of $89.4, which is +105.80% compared to the current price. The earnings rating for Axsome Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Axsome Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Axsome Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.32, ATR14 : 3.41, CCI20 : 28.68, Chaikin Money Flow : 0.05, MACD : 1.03, Money Flow Index : 52.67, ROC : -2.14, RSI : 46.25, STOCH (14,3) : 74.66, STOCH RSI : 1.00, UO : 62.52, Williams %R : -25.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Axsome Therapeutics Inc. in the last 12-months were: Mark Coleman (Buy at a value of $50 181), Mark Coleman (Option Excercise at a value of $4 545), Mark E. Saad (Buy at a value of $107 037), Nick Pizzie (Buy at a value of $33 676), Roger A. Jeffs (Buy at a value of $147 350)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
8 (80.00 %)
9 (81.82 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (10.00 %)
1 (10.00 %)
1 (9.09 %)
Moderate Sell
1 (10.00 %)
1 (10.00 %)
1 (9.09 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.45

Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and others.

CEO: Herriot Tabuteau

Telephone: +1 212 332-3241

Address: 200 Broadway, New York 10038, NY, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

68%32%

Bearish Bullish

60%40%

TipRanks News for AXSM

Thu, 30 Jun 2022 04:57 GMT Axsome Therapeutics (AXSM) Gets a Buy Rating from SVB Securities

- TipRanks. All rights reserved.

Wed, 29 Jun 2022 12:20 GMT Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Axsome Therapeutics (AXSM) and Roche Holding AG (OtherRHHVF)

- TipRanks. All rights reserved.

Mon, 27 Jun 2022 12:28 GMT Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Valneva (VALN)

- TipRanks. All rights reserved.

Wed, 04 May 2022 05:56 GMT Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX), Axsome Therapeutics (AXSM) and Prometheus Biosciences (RXDX)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 03:19 GMT Axsome Therapeutics (AXSM) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Mon, 25 Apr 2022 18:25 GMT Axsome Therapeutics (AXSM) Receives a Buy from Berenberg Bank

- TipRanks. All rights reserved.

Wed, 20 Apr 2022 03:45 GMT Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM) and Checkmate Pharmaceuticals (CMPI)

- TipRanks. All rights reserved.

Thu, 07 Apr 2022 23:55 GMT Axsome Therapeutics (AXSM) Gets a Buy Rating from Berenberg Bank

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 02:36 GMT Axsome Therapeutics (AXSM) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Tue, 29 Mar 2022 12:45 GMT Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Axsome Therapeutics (AXSM) and Reata Pharmaceuticals (RETA)

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 12:42 GMT Axsome Therapeutics (AXSM) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits